EBV status (EBER-ISH on tumor tissue)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BIO-EBV-STATUS |
|---|---|
| Type | Biomarker |
| Aliases | EBEREBVEBV statusEBV статус (EBER-ISH на тканині)Epstein-Barr virus |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-NCCN-BCELL-2025 |
Biomarker Facts
| Biomarker type | viral_load |
|---|---|
| Measurement | MethodEBER (EBV-encoded RNA) in-situ hybridization on FFPE tissue. Serum EBV-DNA quantitative for systemic involvement Unitscategorical (positive | negative); EBV-DNA copies/mL for serum |
| Related biomarkers | None declared |
Notes
Cross-disease etiologic + therapeutic significance: - **Endemic Burkitt** (equatorial Africa): EBV+ in ~95% - **Sporadic Burkitt** (Western): EBV+ in ~15% - **Classical Hodgkin**: EBV+ in ~30-40% (mixed cellularity highest) - **Post-transplant LPD (PTLD)**: EBV-driven; rituximab + reduce immunosuppression often curative - **HIV-associated DLBCL / plasmablastic / primary effusion**: EBV+ common - **NK/T nasal-type lymphoma**: EBV+ universally - **AITL microenvironment**: EBV+ B-cells frequent - **EBV+ DLBCL of elderly** (WHO 5th-ed entity): defined by EBV+ Drives different treatment context: - PTLD → reduce immunosuppression + rituximab - HIV-associated → cART + standard regimen - EBV+ HL has same regimen but PD-1 blockade emerging response differential Currently informational in our KB; not algorithm-driving for treatment selection but documented for clinical context.
Used By
Actionability
BMA-EBV-POSITIVE-GASTRIC- EBV-positive gastric adenocarcinoma is a TCGA-defined molecular subtype (~9% of gastric a...
Biomarker
BIO-EBV-DNA- EBV-DNA viral load (quantitative PCR, plasma)BIO-HIV-STATUS- HIV status (4th-gen Ag/Ab combo screening)
Red flag
RF-AITL-EBV-DRIVEN-B-CELL- AITL with EBV+ B-cell expansion (large B-cells, EBER+ in microenvironment) — risk of seco...